Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Complete cure of advanced hepatocellular carcinoma with right adrenal gland metastasis and portal vein thrombosis by multiple applications of an interdisciplinary therapy: Case report with 8-year follow up

  • Jung, Hojung (Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Kim, Byung Ik (Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Cho, Yong Kyun (Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Jeon, Woo Kyu (Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Kim, Hong Joo (Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Hong, Hyun Pyo (Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • Received : 2017.06.04
  • Accepted : 2017.08.02
  • Published : 2018.12.25
⟨ Previous Next ⟩

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cause of death worldwide and the main cause of primary liver cancer. The principle problem of HCC is the poor prognosis, since advanced HCC reportedly has a median survival of only 9 months. The standard therapies are sorafenib and regorafenib, but the outcomes remain unclear. We report a 60-year-old man with advanced HCC with right adrenal gland metastasis and portal vein tumor thrombosis, who showed a complete response to multiple applications of an interdisciplinary therapy.

Keywords

Acknowledgement

Supported by : Samsung Biomedical Research Institute

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-386. https://doi.org/10.1002/ijc.29210
  2. Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee JK, et al. Prediction of cancer incidence and mortality in Korea, 2016. Cancer Res Treat 2016;48:451-457. https://doi.org/10.4143/crt.2016.092
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. https://doi.org/10.3322/caac.21332
  4. Allaire M, Nault JC. Advances in management of hepatocellular carcinoma. Curr Opin Oncol 2017;29:288-295. https://doi.org/10.1097/CCO.0000000000000378
  5. Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015;7:673-687. https://doi.org/10.4254/wjh.v7.i4.673
  6. Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol 2017;8:256-265. https://doi.org/10.21037/jgo.2016.09.07
  7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390. https://doi.org/10.1056/NEJMoa0708857
  8. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-240. https://doi.org/10.2165/00003495-200969020-00006
  9. Lu LC, Chen PJ, Yeh YC, Hsu CH, Chen HM, Lai MS, et al. Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: a national population study. Anticancer Res 2017;37:2593-2599. https://doi.org/10.21873/anticanres.11604
  10. Moriguchi M, Furuta M, Itoh Y. A review of non-operative treatments for hepatocellular carcinoma with advanced portal vein tumor thrombus. J Clin Trandl Hepatol 2017;5:177-183.
  11. Kim SB. Diffuse infiltrative hepatocellular carcinoma with portal vein tumor thrombosis completely cured by transcatheter arterial chemoembolization: case report with 8-year follow-up. Case Rep Gastroenterol 2016;10:623-628. https://doi.org/10.1159/000452208

Cited by

  1. Long-term sustained complete response with off-therapy to sorafenib in advanced hepatocellular carcinoma: a case report vol.61, pp.5, 2018, https://doi.org/10.2957/kanzo.61.255